The present invention relates to a composition for preventing or treating autoimmune diseases. In particular the present invention relates to a composition that prevents or treats the disease by specifically targeting the immune cells responsible for the autoimmune reaction. Thus one aspect relates to a composition comprising DDA and TDB or MMG, retinoic acid or analogues thereof, and at least one autoimmune antigen for use in prevention or treatment of autoimmune diseases.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
The present invention relates to the field of lipid nanoparticles (LNPs). In particular, the present invention relates to an LNP composition comprising a cationic or cationically ionisable lipid or lipid-like material, a helper lipid, a lipopolymer, and a monomycoloyl glycerol (MMG) analogue. The LNP composition is particularly useful as a vaccine composition.
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
3.
A DNA PLASMID SARS-CORONA VIRUS-2/COVID-19 VACCINE
The present invention relates to DNA vaccine against SARS-Coronavirus-2 (SARS-CoV-2) infection. In particular, the present invention relates to a DNA vaccine encoding the SARS-Coronavirus-2 spike protein for use in prevention or treatment of viral infection in humans and/or animals.
The present invention relates to DNA vaccine against SARS-Coronavirus-2 (SARS-CoV-2) infection. In particular, the present invention relates to a DNA vaccine encoding the SARS-Coronavirus-2 spike protein for use in prevention or treatment of viral infection in humans and/or animals.
The DNA vaccine including the DNA construct has several features in its design that together provide a more safe and broad protection against SARS-Cov-2 strains in humans and animals, e.g. mink, ferrets, pigs and cats. The DNA construct encodes the SPIKE protein derived from the pandemic strain; Wuhan-Hu-1 (MN908947). The sequence is codon optimized for high expression in human and mammalian cells and the DNA construct is inserted in a selected DNA plasmid for eukaryotic in vivo and in vitro expression. The combination of the choice of SARS-COV-2 SPIKE sequence, codon optimization, expression in the new generation eukaryotic expression plasmid with no antibiotic resistance marker (instead the RNA-OUT system is used for safety) and delivery to the very immunogenic skin, results in protection against SARS-COV-2 infection and covid-19 disease.
The Board of Trustees of the Leland Stanford Junior University (USA)
Statens Serum Institut (Danemark)
The Regents of the University of California (USA)
Inventeur(s)
Liang, Liang
Snyder, Michael P.
Melbye, Mads
Chen, Songjie
Rand, Larry
Jelliffe-Pawlowski, Laura
Shen, Xiaotao
Abrégé
Methods to compute gestational age and gestational health and applications thereof are described. Generally, systems utilize analyte measurements to determine a gestational age and gestational health, which can be used as a basis to perform interventions and treat individuals.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
The present invention relates to an adjuvant composition comprising dimethyldioctadecyl ammonium salt (DDA), monomycoloyl glycerol (MMG), and the CpG ODN 2006 oligodeoxynucleotide having SEQ ID NO:1 or a sequence having 90% identity to SEQ ID NO:1. Another aspect of the present invention is a vaccine comprising said adjuvant composition and at least one antigen, and the use of said vaccine in prevention or treatment of an infectious disease.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
The present invention relates to a liposomal composition for use as a medicament. In particular, the present invention relates to a liposomal composition for use in prevention or early treatment of pathogenic infection. More specifically, the liposomal composition is used for prevention, or early treatment, of pathogenic infection in the respiratory tract, preferably by nasal or pulmonary administration.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
The Board of Trustees of the Leland Stanford Junior University (USA)
Statens Serum Institut (Danemark)
Inventeur(s)
Moufarrej, Mira N.
Ngo, Thuy T. M.
Camunas-Soler, Joan
Melbye, Mads
Quake, Stephen R.
Abrégé
The invention is directed to methods of predicting gestational age of a fetus. The invention is also directed to methods of identifying woman is risk for preterm delivery. In some aspects, the methods include quantitating one or more placental or fetal-tissue specific genes in a biological sample from the woman.
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
8.
COMPOSITION FOR PREVENTING OR TREATING AUTOIMMUNE DISEASES
The present invention relates to a composition for preventing or treating autoimmune diseases. In particular the present invention relates to a composition that prevents or treats the disease by specifically targeting the immune cells responsible for the autoimmune reaction. Thus one aspect relates to a composition comprising DDA and TDB or MMG, retinoic acid or analogues thereof, and at least one autoimmune antigen for use in prevention or treatment of autoimmune diseases.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention relates to a method for recombinant production of a fusion protein comprising multiple malaria antigens for inducing immune responses comprising a combination of antibodies. In particular, the fusion proteins of the present invention comprise fragments of both Pfs230 and Pfs48/45 to lower the required threshold of functional antibodies and to reduce the risk of escape mutations. Thus, the fusion proteins of the present invention are suitable for use in a multivalent malaria vaccine.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYAN (USA)
STATENS SERUM INSTITUT (Danemark)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventeur(s)
Liang, Liang
Snyder, Michael, P.
Chen, Songjie
Rand, Larry
Jelliffe-Pawlowski, Laura
Shen, Xiaotao
Abrégé
Methods to compute gestational age and gestational health and applications thereof are described. Generally, systems utilize analyte measurements to determine a gestational age and gestational health, which can be used as a basis to perform interventions and treat individuals.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
The present invention relates to DNA vaccine against SARS-Coronavirus-2 (SARS-CoV-2) infection. In particular, the present invention relates to a DNA vaccine encoding the SARS-Coronavirus-2 spike protein for use in prevention or treatment of viral infection in humans and/or animals. The DNA vaccine including the DNA construct has several features in its design that together provide a more safe and broad protection against SARS-CoV-2 strains in humans and animals, e.g. mink, ferrets, pigs and cats. The DNA construct encodes the SPIKE protein derived from the pandemic strain; Wuhan-Hu-1 (MN908947). The sequence is codon optimized for high expression in human and mammalian cells and the DNA construct is inserted in a selected DNA plasmid for eukaryotic in vivo and in vitro expression. The combination of the choice of SARS-CoV-2 SPIKE sequence, codon optimization, expression in the new generation eukaryotic expression plasmid with no antibiotic resistance marker (instead the RNA-OUT system is used for safety) and delivery to the very immunogenic skin, results in protection against SARS-CoV-2 infection and covid-19 disease.
in vivo in vitro in vitro expression. The combination of the choice of SARS-CoV-2 SPIKE sequence, codon optimization, expression in the new generation eukaryotic expression plasmid with no antibiotic resistance marker (instead the RNA-OUT system is used for safety) and delivery to the very immunogenic skin, results in protection against SARS-CoV-2 infection and covid-19 disease.
The Board of Trustees of the Leland Stanford Junior University (USA)
Statens Serum Institut (Danemark)
Inventeur(s)
Liang, Liang
Urban, Jijuan Gu
Melbye, Mads
Snyder, Michael P.
Abrégé
Methods to compute gestational age and gestational health and applications thereof are described. Generally, systems utilize analyte measurements to determine a gestational age and gestational health, which can be used as a basis to perform interventions and treat individuals.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
14.
LIPOSOMAL COMPOSITION FOR PREVENTING OR EARLY TREATMENT OF PATHOGENIC INFECTION
The present invention relates to a liposomal composition for use as a medicament. In particular, the present invention relates to a liposomal composition for use in prevention or early treatment of pathogenic infection. More specifically, the liposomal composition is used for prevention, or early treatment, of pathogenic infection in the respiratory tract, preferably by nasal or pulmonary administration.
A61P 5/48 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.
A61K 39/118 - Chlamydiaceae, p. ex. Chlamydia trachomatis ou Chlamydia psittaci
C07K 14/295 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Chlamydiales (O)
The present invention relates to fusion proteins based on antigenic polypeptides from Mycobacterium tuberculosis for preventing, inhibiting or treating infections and/or disease caused by a species of the tuberculosis complex. In particular, the present invention relates to fusion proteins comprising antigens that do not prime an immune response against BCG and/or ESAT-6 repeats. The fusion proteins may comprise a combination of early and late antigens. Further, the present invention relates to vaccines, immunogenic compositions and pharmaceutical compositions comprising the fusion proteins.
PfsPfsPfs48/45 to lower the required threshold of functional antibodies and to reduce the risk of escape mutations. Thus, the fusion proteins of the present invention are suitable for use in a multivalent malaria vaccine.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
STATENS SERUM INSTITUTE (Danemark)
Inventeur(s)
Liang, Liang
Urban, Jijuan, Gu
Melbye, Mads
Snyder, Michael, P.
Abrégé
Methods to compute gestational age and gestational health and applications thereof are described. Generally, systems utilize analyte measurements to determine a gestational age and gestational health, which can be used as a basis to perform interventions and treat individuals.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
The present invention relates to improved immunoassays with the use of a heat-treated preparation of Immunoglobulins to reduce false positives. The invention furthermore relates to the use of one or more Fc fragments to reduce false positives in immunoassays.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
Mycobacterium tuberculosis antigens for use in in vivo determination of the presence of Mtb infection in immunocompromised persons or persons co-infected with HIV and the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtb infection infection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.
G01N 33/554 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques le support étant une cellule ou un fragment de cellule biologique, p. ex. cellules de bactéries, de levure
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
STATENS SERUM INSTITUT (Danemark)
Inventeur(s)
Moufarrej, Mira N.
Ngo, Thuy T. M.
Camunas-Soler, Joan
Melbye, Mads
Quake, Stephen R.
Abrégé
The invention is directed to methods of predicting gestational age of a fetus. The invention is also directed to methods of identifying woman is risk for preterm delivery. In some aspects, the methods include quantitating one or more placental or fetal-tissue specific genes in a biological sample from the woman.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The present invention relates to a nucleic acid vaccine. Specifically, the use of a single nucleic acid sequence comprising combinations of influenza genes coding for selected hemagglutinin (HA), neuraminidase (NA), matrix protein 1 (M1), matrix protein 2 (M2) and nucleoprotein (NP) interspaced with selected linkers comprising cleavage sites to produce individual proteins, together forming one polyvalent influenza vaccine for use in medicine for humans and animals.
Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.
A61K 39/118 - Chlamydiaceae, p. ex. Chlamydia trachomatis ou Chlamydia psittaci
C07K 14/295 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Chlamydiales (O)
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
This invention provides for a method for improving the success rate of in vitro fertilization in women hosting abnormal vaginal microbiota. The method comprises the steps of: (i) selecting a woman suspected of hosting abnormal vaginal microbiota (AVM); (ii) administering to the woman a suitable antibiotic administered in an amount and duration effective to reduce the quantity of abnormal vaginal microbiota hosted by the woman; (iii) administering to the woman via vaginal administration an amount of Lactobacillus species in an amount sufficient to colonize the vaginal mucosa; and, (iv) transferring an embryo to the woman.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
In vivo and in vitro diagnostics, other than for medical or
veterinary purposes; diagnostic reagents for scientific and
laboratory use; diagnosis and diagnostic preparations, other
than for medical use. In vivo and in vitro diagnostics for medical and veterinary
purposes; diagnostic reagents for medical and veterinary
use; diagnosis and diagnostic preparations for medical use;
antibodies for diagnostic purposes for medical use.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
In vivo and in vitro diagnostic preparations, other than for medical or veterinary purposes; diagnostic reagents for scientific and laboratory use; diagnosis and diagnostic preparations, other than for medical use In vivo and in vitro diagnostic preparations for medical and veterinary purposes; diagnostic reagents for medical and veterinary use; diagnosis and diagnostic preparations for medical use; antibodies for diagnostic purposes for medical use
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Diagnostic reagents for in vivo and in vitro use in biochemistry, clinical chemistry and microbiology; cell culture reagents for laboratory use; diagnostic reagents for medical-scientific research use
(2) In vivo and in vitro diagnostics for medical and veterinary purposes; Diagnostic reagents for medical and veterinary use; diagnostic reagents for medical diagnostic use; diagnostic reagents for medical and clinical laboratory use; anti-bodies for diagnostic purposes for medical use
A method of controlling the surface charge of liposomes by anchoring hydrophilic coating polymers onto the liposomes by electrostatic interactions using polar tags and adjuvants with changed drainage properties comprising such liposomes.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
32.
Alpha-tocopherol-based adjuvanted solvent for DNA vaccines
The present invention discloses a delivery system for nucleic acid vaccines comprising an emulsion of tocol and esters hereof. Vaccines and new ways of administration of DNA vaccines are disclosed.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
C07D 311/72 - Dérivés dihydro-3, 4 comportant en position 2 au moins un radical méthyle et en position 6 un atome d'oxygène, p. ex. tocophérols
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Vaccines; veterinary vaccines; vaccines for human use;
vaccine adjuvants. Research and development services relating to vaccines;
research and development of vaccines and medicines.
34.
SKIN TESTING FOR TUBERCULOSIS IN IMMUNOCOMPROMISED PERSONS
The present invention discloses the use of Mycobacterium tuberculosisantigens for use in in vivodetermination of the presence of Mtbinfection in immunocompromised persons or persons co-infected with HIVand the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtbinfection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.
The present invention discloses the use of Mycobacterium tuberculosisantigens for use in in vivodetermination of the presence of Mtbinfection in immunocompromised persons or persons co-infected with HIVand the for preparing a diagnostic reagent for skin testing (a skin test reagent) for robust assessment of the presence of Mtbinfection in an individual wherein the individual is an immunocompromised person or a person co-infected with HIV.
The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic reagents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
37.
ALPHA-TOCOPHEROL-BASED ADJUVANTED SOLVENT FOR DNA VACCINES
The present invention discloses a delivery system for nucleic acid vaccines comprising an emulsion of tocol and esters hereof. Vaccines and new ways of administration of DNA vaccines are disclosed.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
The present invention is directed to a fusion protein, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion protein, antigen cocktails and immunological compositions are based on proteins secreted by the ESAT-6 secretion system 1 (ESX-1) and are among the most immunodominant M. tuberculosis (MTB) antigens.
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
39.
Method of diagnosing galactosemia in neonatal screening
A method of diagnosing galactosemia in blood samples from neonates by determining GAL-1-P concentrations before 5-7 days of life is disclosed. The removal of interfering compounds allows a more specific and therefore more accurate determination of GAL-IP levels in newborn screening for galactosemia using mass spectrometry. This is of major importance when investigating samples from children that have not yet achieved a steady state of GAL-IP (i.e. before 5-7 day of life).
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
G01N 33/66 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les sucres du sang, p. ex. le galactose
C12Q 1/54 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir le glucose ou le galactose
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
40.
DIAGNOSTIC REAGENTS FOR IMPROVED IN VIVO OR IN VITRO CELL-MEDIATED IMMUNOLOGICAL DIAGNOSIS OF TUBERCULOSIS
The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic re agents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
41.
DIAGNOSTIC REAGENTS FOR IMPROVED IN VIVO OR IN VITRO CELL-MEDIATED IMMUNOLOGICAL DIAGNOSIS OF TUBERCULOSIS
The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic re agents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemicals and reagents used in science; chemicals for the manufacture of medicines and vaccines; diagnostic preparations, not for medical purposes; bacterial preparations other than for medical and veterinary use. Pharmaceutical and veterinary preparations; vaccines; plasma products for medical purposes; bacterial and fungal cultures for medical purposes; diagnostic preparations for medical purposes; antibodies for medical diagnostic purposes; dietetic substances adapted for medical use; disinfectants; bacterial, vermin and fungal destroying preparations. Providing of training and education. Scientific, medical and biomedical research, including monitoring of illnesses, epidemic illnesses and epidemic readiness services. Medical services; medical clinics and vaccination clinics; blood bank services; pharmaceutical counselling; information on diseases, disease prevention and disease management; Medical care for human beings or animals in the form of monitoring diseases and disease epidemics; epidemic readiness services; healthcare and information on healthcare and personal hygiene.
The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.
C07K 14/295 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Chlamydiales (O)
A61K 39/118 - Chlamydiaceae, p. ex. Chlamydia trachomatis ou Chlamydia psittaci
The present invention describes an efficient vaccine against a Chlamydia trachomatis (Ct). The vaccine is based on recombinant fusion molecules that are capable of generating a high titered neutralizing antibody response that is protective against various Ct serovars. Our invention furthermore describe the combination of these antibody promoting fragments with Ct antigens that are targets for T cells with the aim to provide a vaccine that activate both arms of the immune system.
C07K 14/295 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Chlamydiales (O)
A61K 39/118 - Chlamydiaceae, p. ex. Chlamydia trachomatis ou Chlamydia psittaci
46.
A SINGLE OR MULTISTAGE MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS SUBUNIT VACCINE
The present invention provides one or more immunogenic polypeptides for use in a preventive or therapeutic vaccine against latent or active infection in a human or animal caused by a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis. Furthermore a single or multi-phase vaccine comprising the one or more immunogenic polypeptides is provided for administration for the prevention or treatment of infection with a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis. Additionally, nucleic acid vaccines, capable of in vivo expression of the multi-phase vaccine comprising the one or more immunogenic polypeptides, is provided for prevention or treatment of infection with a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis.
A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p. ex. glutathion
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C12N 15/74 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p. ex. Lactobacillus, Micromonospora
48.
METHOD OF DIAGNOSING GALACTOSEMIA IN NEONATAL SCREENING
A method of diagnosing galactosemia in blood samples from neonates by determining GAL-l-P concentrations before 5-7 days of life is disclosed. The removal of interfering compounds allows a more specific and therefore more accurate determination of GAL- IP levels in newborn screening for galactosermia using mass spectrometry. This is of major importance when investigating samples from children that have not yet achieved a steady state of GAL-IP (i.e. before 5-7 day of life).
G01N 33/66 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les sucres du sang, p. ex. le galactose
49.
METHOD OF DIAGNOSING GALACTOSEMIA IN NEONATAL SCREENING
A method of diagnosing galactosemia in blood samples from neonates by determining GAL-l-P concentrations before 5-7 days of life is disclosed. The removal of interfering compounds allows a more specific and therefore more accurate determination of GAL- IP levels in newborn screening for galactosermia using mass spectrometry. This is of major importance when investigating samples from children that have not yet achieved a steady state of GAL-IP (i.e. before 5-7 day of life).
G01N 33/66 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les sucres du sang, p. ex. le galactose
50.
PCR diagnostics of dermatophytes and other pathogenic fungi
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
51.
DIAGNOSTIC PCR PRIMERS ENABLING EXHAUSTIVE DETECTION OF NON-HUMAN EUKARYOTIC SSU RDNA IN HUMAN CLINICAL SAMPLES
The 18S PCR method is based on the detection of species-specific small subunit (SSU) rDNA, by amplification of all non-human SSU rDNA in human clinical samples. This is obtained by preferential PCR amplification of non-human DNA extracted from human clinical samples, using three or four different primer sets, high human DNA content samples (steril) and low human DNA content samples (fecal), respectively. The resulting PCR amplicons are then barcoded and sequenced using either sanger or NGS sequencing; single molecule sequencing to circumvent the complications of Sanger sequencing (basically most prevalent amplicon sequencing). This will enable the detection of all amplified non-human eukaryotes in the respective clinical sample. The technique is furthermore compatible with the existing 16S method for detection of all bacteria in clinical samples, in order to provide the most complete detection system of organisms in clinical samples to date.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention covers monoclonal antibodies that can be used for i) specific detection of the new PBP variant PBPLGA2SI found in some MRSA isolates and ii) detection of both PBP2a or PBP2'and PBPLGA251 - This will make it possible to detect MRSA expressing PBPLGA251 and integrate these antibodies into in vitro diagnostics for detection of MRSA. This will enhance the sensiti vity of existing MRSA detection tests and ultimately improve infection control.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
The present invention is directed to fusion proteins, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. by Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, Mycobacterium canettii, Mycobacterium pinnipedii or Mycobacterium mungi. The fusion proteins or antigen cocktails are based on ESX secreted or associated proteins e.g. proteins secreted by the ESAT-6 secretion system 1 (ESX-1 ) which are among the most immunodominant M. tuberculosis (MTB) antigens.
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 38/00 - Préparations médicinales contenant des peptides
The present invention relates to an in vitro method for diagnosing a genetic predisposition or susceptibility for cerebral malaria, a severe condition of a Plasmodium falsiparum infection characterized by sequestration of parasitized red blood cells (PRBCs) and non- PRBCs (NPRBCs) in cerebral capillaries and venules and ring-like lesions in the brain. The method comprises detection of at least one specific SNP (rs2073342, rs2233860 or rs8019343) and SNPs which are in linkage disequilibrium therewith. The invention further relates to diagnostic and research kits for use in diagnosing a genetic predisposition or susceptibility for cerebral malaria and to the use of adrenal cortical steroid, inhibitors of tyrosinkinase and anti-ECP Ig in the treatment of cerebral malaria.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present invention relates to a method for the production of correctly folded Pfs48/45. This is achieved in the lactococcus lactis when Pfs48/45 or fractions thereof are fused genetically to a glutamate rich protein, e.g. GLURP from Plasmodium falciparum.
The present invention relates to an in vitro method for diagnosing a genetic predisposition or susceptibility for Infantile Hypertrophic Pyloric Stenosis (IHPS), a severe condition characterized by hypertrophy of the pyloric sphincter muscle. The present invention also relates to diagnostic and research kits for use in diagnosing IHPS and to the use of cholesterol in the treatment of IHPS.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention discloses a method for the formation of liposomes by using high shear mixing of aqueous solution of lipid powder; the lipid powder can be produced by any known technique. Components of the liposomes include but are not limited to cationic lipids, immunostimulators/immunopotentiators and macromolecules as components for the liposome formation. The disclosed method describes the formulation of stable liposomes solitary or complexing high concentrations of macromolecules such as proteins, DNA and RNA having opposite charge of the liposomes by high shear mixing where aggregation is avoided due to the formulation method.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
58.
Tuberculosis vaccines comprising antigens expressed during the latent infection phase
M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
This invention relates to the use of a specific micro-RNA (micro-RNA 17) to monitor disease activity and treat fibrotic disorders such as systemic sclerosis, cirrhosis of the liver, pulmonary sclerosis, retroperitoneal fibrosis and other conditions characterized by excessive pathological collagen accumulation (scarring) in tissues. The micro-RNA 17 is a specific 23 nucleotide single-stranded RNA molecule that is decreased in the circulation of patients with systemic sclerosis and which regulates key collagen telopeptide lysyl hydroxylases involved in pathological crosslinking of collagen. This makes it useful for diagnosing and monitoring fibrosis as well as the basis of drugs or other treatments that upregulate the levels of this miR in fibrosis patients.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
Current method of choice for virus identification in many diagnostic laboratories is specific real-time polymerase chain reaction (PCR), where sequence-specific primer pairs are used for each virus, or a group of viruses. This is a rapid, sensitive and specific method that is easy to perform, but can have limited sensitivity that may lead to falsely negative results. A random pre-amplification of the sample prior to a specific PCR could be helpful in clinical cases where the detection limit of the real-time PCR assay is not sensitive enough. This could be when only very limited amount of sample is available or where the pathogen is present at very low amounts. The present invention discloses a nucleotide amplification method comprising of random unbiased whole genome amplification (WGA) pre-amplification followed by a specific amplification performed in the same vial or tube. The two reaction mixtures are separated by a wax layer so the reaction mixture on top of the wax layer is the pre-amplification mixture and the reaction mixture under the wax layer is the specific amplification mixture. Performing a random pre-amplification before the real-time PCR would considerably increase the sensitivity of the specific real-time PCR when testing samples with expected low copy number or precious and irretrievable samples. Performing the two reactions after each other in the same tube minimize the risk for PCR contamination since no transfer of pre-amplified sample is needed. The described method would work on any DNA of any origin, both from non-cellular sources (virus) and from cellular sources (bacteria, archae, eukaryotes), as well as on cDNA.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
The invention concerns nucleotides vaccines encoding influenza proteins with few or no glycosylation sites. Since these first introductions of pandemic influenzas the viruses have drifted, accumulating mutations at antigenic sites, but also the N-glycosylation pattern has changed during the drifted years, accumulating N-linked glycosylation sequons that help mask the antigenic sites for recognition by the host immune system. These “naked” initial haemagglutinins induce a broad cross reactivity against widely drifted influenza subtypes. The origin of the DNA or RNA can be both pandemic influenza strains, which codes for proteins which have a naturally low content of glycosylation sites and/or DNA or RNA from non-pandemic influenza strains where the nucleotides have been mutated or changed so it encodes for proteins with less or no glycosylation sites. The invention also discloses DNA or RNA encoding the haemagglutinin (HA) from pandemic influenza A, e.g. the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, optionally with the Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from these pandemic influenza virus included, mixed together with DNA or RNA from non-pandemic influenza A as a vaccine against present day and future influenza A viruses.
MRSA CC398 is a clone of S. aureus that has recently emerged in pigs and other domestic animals worldwide. As any other MRSA, the clone displays high levels of antibiotic resistance and poses a serious threat to human health because of the risk of antibiotic treatment failure in human patients. We developed a new diagnostic test for identification of MRSA CC398 using a single one-step PCR that is very easily performed within a few hours. The test is based on the principle that clonal differences within S. aureus are reflected in the sequence of a gene (sau1hsdS1) located on the chromosome of this bacterial species. Accordingly, such a gene represents an optimal target for S. aureus and MRSA identification at the clone level. The test includes detection of the gene conferring methicillin resistance (mecA), therefore allowing rapid discrimination between methicillin-susceptible and methicillin-resistant variants of the clone. A preliminary validation of the test was performed on a collection of CC398 and non-CC398 strains, resulting in 100% sensitivity and 100% specificity. The test can be combined to real-time PCR technology to further reduce simplify the test performance as well as to allow quantification of the target MRSA clone in biological specimens. The invention has important applications related to surveillance and control of MRSA CC398 in humans, animals and food products.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
M. bovis BCG (Copenhagen) capable of stimulating and activating human DC's at exceedingly low doses. In addition to their direct role as immunostimulators of human DC's we demonstrate their use in the development of a new generation of adjuvants suitable for human administration. We furthermore identify a number of highly active synthetic MMG analogues with great potential in cancer treatment, and for vaccine adjuvants against both infectious disease and disorders like Alzheimers disease.
The present invention discloses a vaccine or immunogenic composition that can be administred to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis., M.bovis, M.africanum), The invention is base on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
The present invention discloses a vaccine or immunogenic composition that can be administred to latently infected individuals to prevent reactivation of latent tuberculosis infection caused by species of the tuberculosis complex microorganisms (Mycobacterium tuberculosis., M.bovis, M.africanum), The invention is base on a number of M. tuberculosis derived proteins and protein fragments which are constitutively expressed in different stages of the infection. The invention is directed to the use of these polypeptides, immunologically active fragments thereof and the genes encoding them for immunological compositions such as vaccines.
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
Described herein are vaccines and the use of naked DNA and/or RNA encoding hemagglutinin (HA) from pandemic influenza, e.g., the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus, as a vaccine component against present day and coming H1, H2, H3, H5, N1, N2 containing influenza A infections in humans and swine optionally with the naked DNA and/or RNA encoding Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be “humanized” using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and/or the nucleoprotein (NP) from the 1918 influenza strain is also disclosed.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
The invention concerns nucleotides vaccines encoding influenza proteins with few or no glycosylation sites. Since these first introductions of pandemic influenzas the viruses have drifted, accumulating mutations at antigenic sites, but also the N-glycosylation pattern has changed during the drifted years, accumulating N-linked glycosylation sequons that help mask the antigenic sites for recognition by the host immune system. These "naked" initial haemagglutinins induce a broad cross reactivity against widely drifted influenza subtypes. The origin of the DNA or RNA can be both pandemic influenza strains, which codes for proteins which have a naturally low content of glycosylation sites and/or DNA or RNA from non-pandemic influenza strains where the nucletides have been mutated or changed so it encodes for proteins with less or no glycosylation sites. The invention also discloses DNA or RNA encoding the haemagglutinin (HA) from pandemic influenza A, e.g. the 1918 H1N1 and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus,, optionally with the Neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from these pandemic influenza virus included, mixed together with DNA or RNA from non-pandemic influenza A as a vaccine against present day and future influenza A viruses.
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
The present invention relates to the use of vaccines with adjuvants comprising cationic liposomes where neutral lipids has been incorporated into the liposomes to change the gel-liquid phase transition and thereby modifying the IgG sub-type response and enhancing the CD 8 response of the liposomal adjuvant. This technology can be used to increase the production of IgG2 antibodies. This sub-type of antibodies (IgG2 in mice corresponding to IgG3 in humans) have been shown to selectively engage Fc activatory receptors on the surface of innate immune cells leading to enhanced proinflammatory responses and thereby a more efficient immune response with higher levels of protection in animal models of e.g. malaria and Chlamydia. The use of adjuvants which selectively give rise to higher levels of IgG2 antibodies will improve the effect of vaccines e.g. against intracellular infections. Furthermore the technology can be used to induce a CD8 response which has been reported to improve the effect of vaccines against e.g. HPV, HIV, influenza and cancer.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
A61K 39/118 - Chlamydiaceae, p. ex. Chlamydia trachomatis ou Chlamydia psittaci
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
The present invention relates to an immunological method and, more particularly, a method for measuring cell-mediated immune reactivity (CMI) in mammals based on the production of IP-10. The invention further discloses an assay and a kit for measuring CMI to an antigen using whole blood or other suitable biological samples. The methods of the present invention are useful in therapeutic and diagnostic protocols for human, livestock and veterinary and wild life applications, thus the invention further relates to a method for diagnosing an infection in a mammal.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
Vaccination with the combination of Ag85B-TB10.4 and IC31 generated a high amount of polyfunctional CD4+T cells expressing high levels of IFN-γ, TNF-α, and IL-2. This in turn led to significant protection against infection with M. tuberculosis in the mouse aerosol challenge model of tuberculosis. Importantly, our results also showed that both the irnmuno- genicity of the vaccine and its ability to protect against TB infection was highly dependent on the antigen dose. Thus, whereas the standard antigen dose of 5.0μg, as well as 15.0μg, did not induce significant protection against M. tuberculosis, reducing the dose to 0.5 μg increased both the immunogenicity of the vaccine as well as its protective efficacy to a level comparable to that observed in BCG vaccinated mice. Thus, the adjuvant IC31®, with the optimal antigen dose, can induce a strong protective Th1 response against M. tuberculosis.
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
73.
COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS
The present invention pertains to the need for novel, reliable, fast and inexpensive approaches to diagnosing, including detecting and characterising microbial infections in humans and animals or methods for detecting and characterising microbial infections in various environments, such as in a food or feed sample. The present invention provides compositions, platforms, kits and methods for diagnosing, detecting and/or characterising a microbial infection or contamination. In particular the present invention relates to such compositions, platforms, kits and methods for diagnosing, detecting and/or characterising a urinary tract infection.
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
C12Q 1/08 - Détermination quantitative utilisant des milieux polyvalents
C12M 1/16 - Appareillage pour l'enzymologie ou la microbiologie contenant ou adaptés pour contenir des milieux solides
Here we identify MMG and its alpha- and ketomycolic acid derivatives as highly bioactive lipids derived from M. bovis BCG (Copenhagen) capable of stimulating and activating human DC's at exceedingly low doses. In addition to their direct role as immunostimulators of human DC's we demonstrate their use in the development of a new generation of adjuvants suitable for human administration. We furthermore identify a number of highly active synthetic MMG analogues with great potential in cancer treatment, and for vaccine adjuvants against both infectious disease and disorders like Alzheimers disease.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
Here we identify MMG and its alpha- and ketomycolic acid derivatives as highly bioactive lipids derived from M. bovis BCG (Copenhagen) capable of stimulating and activating human DC's at exceedingly low doses. In addition to their direct role as immunostimulators of human DC's we demonstrate their use in the development of a new generation of adjuvants suitable for human administration. We furthermore identify a number of highly active synthetic MMG analogues with great potential in cancer treatment, and for vaccine adjuvants against both infectious disease and disorders like Alzheimers disease.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
The invention concerns vaccines and the use of the naked DNA and/or RNA molecule encoding hemagglutinin (HA) from pandemic influenza, e.g. the 1918 HlNl and/or the 1957 H2N2 and/or the 1968 H3N2 influenza A virus and/or the high pathogenic bird pandemic ATV strain (A/buzzard/Denmark/6370/06(H5Nl)) and/or 2001 H5N7 low pathogenic Avian influenza virus (ATV) strain (A/Mallard/Denmark/64650/03(H5N7)) or the March 2006 Denmark H5N1 high pathogenic AIV strain (A/buzzard/Denmark/6370/06(H5Nl)) or the 2008 (A/duck/Denmark/53- 147-8/08 (H7N1)) or the 2004 (A/widegeon/Denmark/66174/G18/04 (H2N3)) as a vaccine component against present day and coming Hl, H2, H3, H5, H7, Nl, N2, N3 containing influenza A infections in humans and/or swine optionally with the naked DNA and/or RNA molecule encoding neuraminidase (NA) and/or matrix protein (M) and/or the nucleoprotein (NP) from pandemic influenza virus included. If the vaccine components are used as DNA or RNA vaccines with or without the corresponding protein, the codons can optionally be 'humanized' using preferred codons from highly expressed mammalian genes and the administration of this DNA vaccine can be by saline or buffered saline injection of naked DNA or RNA, or injection of DNA plasmid or linear gene expressing DNA fragments coupled to particles. Addition of the matrix protein (M) and/or the nucleoprotein (NP) as protein or DNA from the 1918 influenza strain is also disclosed.
Methods based on serogroup specific DNA sequences and subgroup- specific gene of Lpn serogroup (sg) 1 strains for detection and discrimination of all monoclonal Lpn sg 1 Pontiac and non-Pontiac subgroups in clinical and environmental samples are described. Primers were designed for the Lipopolysaccharide (LPS) associated (lag-1) gene, which codes for a common LPS epitope specific for the MAb 3/1 of the Dresden monoclonal panel (sg 1 'Pontiac' subgroups), and primers for open reading frame 2 (ORF 2) DNA sequence of the LPS biosynthesis gene cluster of Lpn sg 1. PCR with primers to the lag-l gene and ORF 2 can be used for diagnosis of LD caused by Lpn sg 1 without need for isolation by culture. The PCR method can be used as a rapid method for detection and discrimination between the Pontiac and non-Pontiac subgroups of Lpn sg 1 in clinical and environmental samples before culture and serogroup results can be obtained. The PCR and DNA methods based on lag-1 gene and ORF 2 DNA sequences could be a valuable tool in outbreak investigations and in risk assessment.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
78.
SCREENING METHOD USING SAMPLE ADSORPTION ON FILTER PAPER
The present invention discloses a diagnostic test and method comprising mixing blood or another biological fluid sample with' a test compound and spotting the blood or the biological fluid on filter paper for subsequent analysis of the effect of the test compound on the blood or on the biological fluid. The biological fluid can be a cerebrospinal fluid, a peritoneal fluid, a cyst fluid, an amniotic fluid, a lavage fluid, a saliva, a. cell extract or a tissue extract. The test compound is chosen among an amino acid, a peptide, a protein, a carbohydrate, an oligosaccharide, a polysaccharide, a glycoprotein, a lipid, a lipoprotein, a glycosa- minoglycan, a hormone, a steroid, a vitamin, a low molecular weight synthetic or natural compound which influences the blood or the biological fluid to cause an alteration of its composition e.g. a toxin, allergen, autoantigen, bacterial protein or polysaccharide, viral protein, fungal protein or polysaccharide, parasitic protein or polysaccharide, bacterial lipopolysaccharide or any other compound relevant to diseases.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
The present invention relates to an immunological method and, more particularly, a method for measuring cell-mediated immune reactivity (CMI) in mammals based on the production of IP-10.The invention further discloses an assay and a kit for measuring CMI to an antigen using whole blood or other suitable biological samples. The methods of the present invention are useful in therapeutic and diagnostic protocols for human, livestock and veterinary and wild life applications, thus the invention further relates to a method for diagnosing an infection in a mammal.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
80.
EXPANDING THE T CELL REPERTOIRE TO INCLUDE SUBDOMINANT EPITOPES BY VACCINATION WITH ANTIGENS DELIVERED AS PROTEIN FRAGMENTS OR PEPTIDE COCKTAILS
The present invention teaches a convenient way of inducing a broad recognition of dominant and subdominant responses to epitopes of any given antigen of importance for prophylaxis or treatment of a chronic disease by immunizing with pools of overlapping fragments (synthetic peptides e.g. 10-30 mers with 2-20 aa overlap) of the desired antigen in appropriate adjuvants. The T cell repertoire is primed to include not only the immunodominant epitope recognized when the intact molecule is used for immunization and induced by the chronic infection itself, but induce a much broader and balanced response to a number of the subdominant epitopes as well. The resulting T-cell response to subdominant epitopes is important for protection against chronic diseases that on their own induces a response focused only towards immunodominant epitopes. The major advantage of the present invention is that it requires no prior knowledge of the precise localisation and identity of the subdominant epitopes and their recognition in a human population, but expands the T-cell repertoire and thereby the total number of epitopes recognized by specific T cells primed by vaccination from a few immunodominant epitopes to multiple of epitopes of vaccine relevance. For chronic disease controlled by humoral immunity the T helper cell response primed by the peptide mix may conveniently be boosted by the full size protein for maximum induction of an antibody response as well.
The present invention provides a composition of amino acid sequences including minimal CTL epitopes identified in the viral proteins Gag, Pol, Env, Vif, Vpr, and Vpu and variants hereof. The composition is contemplated as a therapeutic vaccine, in particular a tailor-made therapeutic vaccine. Further, the invention provides a nucleic acid molecule comprising a sequence of nucleic acids encoding amino acids according to the invention. Also provided are the use of said composition in medicine and for the manufacture of a medicament for in the manufacture of a medicament for the prevention and/or treatment of human immunodeficiency virus infections, a method for preparing the composition and a method of treating an individual being infected with a human immunodeficiency virus or reducing the risk of infection with a human immunodeficiency virus.
The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more starvation antigens from M. tuberculosis, the units of the fusion polypeptide being M. tuberculosis antigens. Further, the invention is related to the use of a vaccine comprising a fusion polypeptide sequence or nucleic acid sequence of the invention given at the same time as BCG, either mixed with BCG or administered separately at different sites or routes for preparing said immunogenic composition, vaccine, or pharmaceutical composition.
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
83.
PCR DIAGNOSTICS OF DERMATOPHYTES AND OTHER PATHOGENIC FUNGI
Dermatophytes which belong to one of the three genera Epidermophyton, Trichophyton and Microsporum are the main cause of fungal infections of skin, hair and nails. Traditional diagnostic procedures consist of microscopy and culture, but due to the slow growth rate of dermatophytes typically two to four weeks are needed before a final diagnosis is obtained. The present invention is a rapid DNA extraction method extracting nucleic acids from fungi (e.g. dermatophytes and other pathogenic fungi) which can be performed from directly on hair, nail or skin specimens from humans, from naturally or experimentally infected animals or from cultured fungal colonies for the use in PCR amplification and detection assays. The present invention also includes specific primer sets for detection of any dermatophyte and for species specific detection of Trichophyton rubrum and Epidermophyton floccosum by PCR and a kit for diagnosing fungal infections.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical products and reagents for scientific purposes;
chemical additives and agents for use in the manufacture of
drugs and vaccines; diagnostic preparations for scientific
and research use; bacteria preparations for scientific and
research use. Pharmaceutical and veterinary preparations, including
anti-toxins namely for the treatment of tuberculosis,
tetanus, diphtheria, polio, whooping cough, measles,
rubella, mumps, encephalitis, malaria, chlamydia, cancer,
HIV, influenza, haemophilus influenza-B, variola, pox virus
and smallpox; vaccines, including vaccine adjuvants;
bacteria and fungus cultures for medical use namely as
reagents and additives for illness diagnostic test kits;
antibodies for medical diagnosis of illnesses; dietetic food
adapted for medical purposes. Scientific, medical and biomedical research.
Lactococcus lactis as a secreted recombinant GLURP-MSP3 hybrid protein and experiments showed that the GLURP-part of the hybrid increased the overall antibody response. Immunizations with the hybrid protein consistently generated a stronger antibody response against the individual GLURP and MSP3 domains than a mixture of the two recombinant molecules injected at one site or the individual recombinant molecules injected simultaneously at two different sites. The difference was most pronounced for the MSP3-specific antibody response suggesting that T cell epitopes located in the GLURP RO-region provide help for B-cell epitopes in the MSP3 region. Moreover, when the animals were injected with a mixture of GLURP and MSP3, individual mice tended to mount a predominant antibody response against either molecule: in some animals GLURP was immunodominant whereas in other animals MSP3 was the dominant immunogen. Additionally, the hybrid was also more antigenic than the individual recombinant proteins since the ELISA-titer of naturally occurring IgG antibodies, in clinically immune African adults, against the hybrid protein was higher than the titers against the individual recombinant proteins. The hybrid protein was also demonstrated to be a potential protective antigen as mouse anti-GLURP-MSP3 IgG antibodies were able to inhibit parasite-growth in vitro in a monocyte-dependent manner.
The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 39/015 - Antigènes d'Hemosporidia, p. ex. antigènes de Plasmodium
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61K 39/118 - Chlamydiaceae, p. ex. Chlamydia trachomatis ou Chlamydia psittaci
87.
Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
The present invention relates to liposome formulations that are physically stable. In particular the present invention relates to steric stabilization of cationic liposomes by incorporating glycolipids into the liposomes. The stabilized liposomes can be used either as an adjuvant for antigenic components or as a drug delivery system. In particular the invention relates to vaccines with adjuvants in aqueous media for immunization, where the final product is stable.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Chemicals and reagents used in science; chemicals for the manufacture of medicines and vaccines; diagnostic preparations, not for medical purposes; bacterial preparations other than for medical and veterinary use. Pharmaceutical and veterinary preparations; antitoxins; vaccines; vaccine adjuvants; bacterial and fungal cultures for medical purposes; diagnostic preparations for medical purposes; antibodies for medical diagnostic purposes; dietetic substances adapted for medical use. Providing of training and education. Scientific, medical and biomedical research. Medical services; medical clinics and vaccination clinics; blood bank services; pharmaceutical counselling; information on diseases, disease prevention and disease management; monitoring diseases and disease epidemics; epidemic readiness services; healthcare and information on healthcare and personal hygiene.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical products and reagents for scientific purposes, namely, biomedical compounds in the form of [ adjuvants, antigens, ] antiserum, [ peptide substrates, enzyme substrates, growth substrates, ] bacterial strains [, chemical and biological indicators used in detection of drug candidates for laboratory and research use, biological tissue in the form of blood and serum for scientific and medical research use; chemical additives and agents for use in the manufacture of drugs and vaccines; diagnostic preparations for scientific and research use; bacteria preparations for scientific and research use ] [ Pharmaceutical preparations, veterinary preparations, and anti-toxins, all for the treatment of tuberculosis, tetanus, diphtheria, polio, whooping cough, measles, rubella, mumps, encephalitis, malaria, chlamydia, cancer, HIV, influenza, haemophilus influenza-B, variola, pox virus and smallpox; vaccines, including vaccine adjuvants; ] bacteria and fungus cultures for medical use, namely, as reagents and additives for illness diagnostic test kits; antibodies for medical diagnosis of illnesses [ ; dietetic food adapted for medical purposes ] [ Scientific, medical and biomedical research ]
90.
ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES
The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldioctadecylammonium-bromide/chloride (DDA) and a lipid extract from The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium- bromide/chloride (DDA) and a lipid extract from Mycobacterium bovis BCG. Mycobacterium bovis BCG. The total lipid extract contains both apolar 1ipids, polar lipids, and lipids of intermediate polarity of which the apolar lipids were found to induce the most powerful immune responses. The total lipids may be extracted with chloroform/methanol and re-dissolved in water before the addition of surfactant. This preparation may be used to induce prominent cell-mediated immune responses in a mammal in order to combat pathogens, or as a treatment for cancer.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Information and counselling concerning diseases and illnesses, disease and illness prevention and disease and illness treatment, including information and counselling concerning vaccines.
